Compare Comfort Systems USA Inc (FIX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Comfort Systems USA Inc vs Gilead Sciences, Inc. — how do they compare? Comfort Systems USA Inc trades at $1,667.4 (market cap $61.14B), while Gilead Sciences, Inc. trades at $135.3 (market cap $163.51B). The key difference: Gilead Sciences, Inc. is far larger — about 2.7× Comfort Systems USA Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| FIX | GILD | |
|---|---|---|
Market Cap | $61.14B | $163.51B |
Sector | Technology | Health |
52-Week High | $2.07K | $155.80 |
52-Week Low | $532.14 | $108.22 |
Enterprise Value | $60.42B | $178.05B |
Dividend Yield | 0.15% | 2.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Comfort Systems USA (FIX) trades at $1,655.80, down 6.72% over the past day, amid a bearish technical signal. The stock shows strong fundamentals with Q1 2026 EPS beating estimates at $10.51 versus $6.81 expected, and revenue growth projected from $9.10B in 2025 to $10.10B in 2026. Analyst consensus remains bullish with a $2,100 price target, supported by robust cash flow and a 53.29% ROE.
Outlook is positive due to AI infrastructure demand and record backlog, though high valuation multiples (P/E 50.14) and execution risks from rapid growth pose challenges. The stock offers growth potential but requires monitoring of margin sustainability and competitive pressures in the contracting services sector.
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Comfort Systems USA Inc
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
